Cerebrolysin vs GB-115
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: FPE 1070
Cerebrolysin is not a single peptide but a mixture: a preparation of small peptides and free amino acids made by enzymatically breaking down purified porcine (pig) brain protein, manufactured by EVER Neuro Pharma in Austria. It is given by injection and is approved as a prescription drug in dozens of countries for stroke, traumatic brain injury, and dementia, but it is not FDA-approved in the United States. Despite decades of use abroad, the human evidence remains genuinely contested.
Also: Ranquilon, N-phenylacetyl-L-prolylglycine ethyl ester
GB-115 is a synthetic dipeptide anxiolytic developed in Russia, chemically the amide of N-phenylhexanoyl-glycyl-L-tryptophan and described as a retro-analogue of cholecystokinin-4. Rather than acting like a benzodiazepine, it blocks cholecystokinin receptors, a different anti-anxiety route. It has been studied in animals and in a small pilot human study, but it is not an approved or widely available medication.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Cerebrolysin | GB-115 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The proposed idea is that Cerebrolysin's small peptides act like the body's own neurotrophic factors, the molecules such as BDNF and NGF that help neurons survive, grow, and form connections. Researchers hypothesize it engages neurotrophic signaling pathways and may protect neurons from injury and support repair after stroke or brain trauma. It is important to be clear that the exact active components and mechanism are not fully defined, partly because it is a complex biological mixture rather than one purified molecule. So the neurotrophic-mimic story is a plausible hypothesis supported by some lab data, not a precisely mapped pathway. | Cholecystokinin (CCK) is a peptide that acts as a neurotransmitter in the brain, and activating its CCK-2 (also called CCK-B) and CCK-1 receptors tends to trigger anxiety and panic-like states. GB-115 works as an antagonist at these cholecystokinin receptors, meaning it occupies the receptor and blocks CCK from setting off that anxiety signaling. In animal work it specifically prevented anxiety provoked by CCK-4, which shares a pharmacological target with GB-115. This CCK-blocking mechanism is the proposed explanation for its calming effect, and it is distinct from the GABA system that classic sedatives act on. |
| Common Dosing | 20-32 mg/day subcutaneous (60mg vial reconstituted in 3 mL bac water = 20 mg/mL) Once or twice daily, split doses above 20 mg into AM/PM, gradual titration | 6 mg daily (2 mg three times daily) 2-3 times daily (morning, afternoon, evening) |
| Administration | Subcutaneous (research) or intravenous/intramuscular (clinical literature) | Oral tablets or sublingual |
| Typical Duration | 8-16 week protocols for research-scale subQ; 10-20 day cycles for clinical IV | 21+ days in clinical trials, effects noted by day 7 |
| Best Time to Take | Morning | Morning and throughout the day |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Cerebrolysin has been tested in many human trials, but the quality and consistency of that evidence is the real story. A Cochrane systematic review on vascular dementia (Cui and colleagues, 2019) concluded that intravenous Cerebrolysin may improve cognition and global function, but cautioned the findings were not definitive because of high risk of bias and heterogeneity across studies. Cochrane reviews of acute ischemic stroke have similarly found insufficient or inconclusive evidence and have flagged a possible signal of increased non-fatal serious adverse events in some analyses. The Alzheimer's Drug Discovery Foundation's Cognitive Vitality review rates the human evidence as mixed and far from conclusive. So while it is a real, widely prescribed drug in many countries, the claim that it reliably improves brain outcomes is not established to Western regulatory standards, and many of the supporting trials come from a narrow set of investigators and sponsors. | The research record is real but thin and almost entirely from a single Russian group. In rodent studies (rats, BALB/c and C57Bl/6 mice), GB-115 reduced anxiety induced by CCK-4 and by yohimbine, with effects that varied by mouse strain, and it stayed effective after long-term dosing without producing tolerance or a withdrawal syndrome when stopped. Preclinical safety work has also been published. The only human data comes from a small pilot clinical study of 25 patients with generalized anxiety disorder given 6 mg daily for 21 days, where anxiety scores on the Hamilton scale fell substantially and fatigue scores improved. Importantly, that study was a single-arm pilot with no placebo or control group, so it cannot prove the drug caused the improvement. There are no large randomized controlled trials, no Western regulatory approval, and the evidence base remains preliminary. |
Frequently Asked Questions: Cerebrolysin vs GB-115
What is the difference between Cerebrolysin and GB-115?
Cerebrolysin is a cognitive peptide that cerebrolysin is not a single peptide but a mixture: a preparation of small peptides and free amino acids made by enzymatically breaking down purified porcine (pig) brain protein, manufactured by ever neuro pharma in austria. it is given by injection and is approved as a prescription drug in dozens of countries for stroke, traumatic brain injury, and dementia, but it is not fda-approved in the united states. despite decades of use abroad, the human evidence remains genuinely contested. GB-115 is a cognitive peptide that gb-115 is a synthetic dipeptide anxiolytic developed in russia, chemically the amide of n-phenylhexanoyl-glycyl-l-tryptophan and described as a retro-analogue of cholecystokinin-4. rather than acting like a benzodiazepine, it blocks cholecystokinin receptors, a different anti-anxiety route. it has been studied in animals and in a small pilot human study, but it is not an approved or widely available medication. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Cerebrolysin or GB-115?
Neither is universally "better" - the choice depends on your specific goals. Cerebrolysin is typically used for cognitive purposes, while GB-115 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Cerebrolysin and GB-115 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Cerebrolysin and GB-115 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.